SLC5A2 and type 2 diabetes mellitus: Specifically, in patients with T2DM, SGLT2 inhibitors were discovered to reduce elevated serum creatinine levels, lower the rate of macroalbuminuria development, and reduce the likelihood of a need for hemodialysis 23.